Stock Price Quote

RPG LIFE SCIENCES LTD.

NSE : RPGLIFEBSE : 532983ISIN CODE : INE105J01010Industry : Pharmaceuticals & DrugsHouse : RPG Enterprises
BSE1513.85-6.85 (-0.45 %)
PREV CLOSE ( ) 1520.70
OPEN PRICE ( ) 1532.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 816
TODAY'S LOW / HIGH ( )1503.00 1555.00
52 WK LOW / HIGH ( )745 1740
NSE1511.35-9 (-0.59 %)
PREV CLOSE( ) 1520.35
OPEN PRICE ( ) 1528.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13046
TODAY'S LOW / HIGH( ) 1501.25 1560.20
52 WK LOW / HIGH ( )748.6 1740
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 2007
Management Info
Harsh Goenka - Chairman Yugal Sikri - Managing Director
Registered Office

Address R P G House , 463,Ceat Mahal,Dr. Annie Besant Road, Worli,
Mumbai,
Maharashtra-400030

Phone 022 - 24981650 / 24986375

Email info@rpglifesciences.com

Website www.rpglifesciences.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

12Mar RPG Life Sciences signs Share Subscrip
RPG Life Sciences has signed Share Subscription and Shareholders' agreem..
20Dec RPG Life Sciences informs about detail
RPG Life Sciences has enclosed intimation of the loss of share certifica..
19Oct RPG Life Sciences to execute power del
RPG Life Sciences has received approval for execution of Power Delivery..
19Oct RPG Life Sciences gains on geting nod
RPG Life Sciences is currently trading at Rs. 1426.00, up by 19.60 point..
19Oct RPG Life Sciences informs about invest
RPG Life Sciences has informed that it enclosed a copy of Investor Prese..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit264.6676.400000000001
Gross Profit 355.4 916.800000000001
Operating Profit 398.21074.9
Net Sales 15375128.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2542.60 (12.29%)
M.Cap ( in Cr)1570.82
Neuland Laboratories (BSE)
peergroup  7654.80 (1.79%)
M.Cap ( in Cr)9821.02
Mankind Pharma (BSE)
peergroup  2397.40 (5.05%)
M.Cap ( in Cr)96037.07
Sanofi India (BSE)
peergroup  8470.70 (0.89%)
M.Cap ( in Cr)19508.55
Solara Active Pharma (BSE)
peergroup  474.10 (12.15%)
M.Cap ( in Cr)1706.58

Shareholding Pattern

PROMOTERS 72.81%
NON-INSTITUTION 24.86%
MUTUAL FUNDS/UTI 1.08%
FI/BANKS/INSURANCE 0.52%
GOVERNMENT 0%
FII 0%

About RPG Life Sciences Ltd.

RPG Life Sciences Ltd. was incorporated in the year 2007. Its today's share price is 1513.85. Its current market capitalisation stands at Rs 2503.76 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5547.7 Cr and Total Income of Rs.5176.1 Cr. The company's management includes Rajat Bhargava, Sachin Nandgaonkar, Bhaskar Iyer, Zahabiya Khorakiwala, Narendra Ambwani, Manoj K Maheshwari, Lalit S Kanodia, Mahesh S Gupta, Yugal Sikri, Harsh Goenka, Rajesh Shirambekar.

It is listed on the BSE with a BSE Code of 532983 , NSE with an NSE Symbol of RPGLIFE and ISIN of INE105J01010. It's Registered office is at R P G House , 463,Ceat Mahal,Dr. Annie Besant Road, WorliMumbai-400030, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, Lovelock & Lewes, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.